Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The minor groove of double-stranded DNA, specifically at sequences rich in adenine (A) and thymine (T), is a critical structural target for a variety of small-molecule ligands and proteins (nih.gov, 2000; oup.com, 1993). AT-rich regions are characterized by a narrow, deep groove and a well-defined spine of hydration, which provides a unique shape and electrostatic environment that favors the binding of crescent-shaped molecules through van der Waals forces and hydrogen bonding (nih.gov, 2012; atdbio.com). Biologically, these regions are essential for the binding of architectural proteins and transcription factors, such as the TATA-binding protein (TBP), which are necessary for the initiation of transcription and DNA replication (nih.gov, 2000; researchgate.net, 2025). Drugs targeting the AT-rich minor groove, known as minor groove binders (MGBs), can displace the spine of hydration and disrupt these vital protein-DNA interactions, leading to the inhibition of gene expression and cell cycle progression (researchgate.net, 2013; nih.gov, 2000). Clinically, MGBs like pentamidine and diminazene are used as antiparasitic agents, often targeting the AT-rich kinetoplast DNA in pathogens, while others like CC-1065 derivatives have been explored for cancer therapy (nih.gov, 2012; researchgate.net, 2012). However, the development of these agents is often limited by non-specific toxicity and potential genotoxicity due to their interaction with the host genome (nih.gov, 2012; nih.gov, 2000).
Non-covalent binding to the minor groove of AT-rich DNA; displacement of the spine of hydration; competitive inhibition of DNA-binding proteins such as transcription factors; interference with DNA replication and transcription; induction of DNA damage and apoptosis.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double-stranded DNA minor groove at AT-rich sequences (DNA minor groove (AT-rich)).